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Experiments using P2X3 knock-out mice or more general P2X receptor antagonists suggest
that P2X3 receptors contribute to visceral hypersensitivity. We aimed to investigate the ef-
fect of the selective P2X3 antagonist A-317491 on visceral sensitivity under physiological
conditions, during acute colitis and in the post-inflammatory phase of colitis.
Methods
Trinitrobenzene sulphonic-acid colitis was monitored by colonoscopy: on day 3 to confirm
the presence of colitis and then every 4 days, starting from day 10, to monitor convales-
cence and determine the exact timepoint of endoscopic healing in each rat. Visceral sensi-
tivity was assessed by quantifying visceromotor responses to colorectal distension in
controls, rats with acute colitis and post-colitis rats. A-317491 was administered 30 min
prior to visceral sensitivity testing. Expression of P2X3 receptors (RT-PCR and immunohis-
tochemistry) and the intracellular signalling molecules cdk5, csk and CASK (RT-PCR) were
quantified in colonic tissue and dorsal root ganglia. ATP release in response to colorectal
distension was measured by luminiscence.
Results
Rats with acute TNBS-colitis displayed significant visceral hypersensitivity that was dose-
dependently, but not fully, reversed by A-317491. Hypersenstivity was accompanied by an
increased colonic release of ATP. Post-colitis rats also displayed visceral hypersensitivity
that was dose-dependently reduced and fully normalized by A-317491 without increased
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release of ATP. A-317491 did not modify visceral sensitivity in controls. P2X3 mRNA and
protein expression in the colon and dorsal root ganglia were similar in control, acute colitis
and post-colitis groups, while colonic mRNA expression of cdk5, csk and CASK was in-
creased in the post-colitis group only.
Conclusions
These findings indicate that P2X3 receptors are not involved in sensory signaling under
physiological conditions whereas they modulate visceral hypersensitivity during acute
TNBS-colitis and even more so in the post-inflammatory phase, albeit via different mecha-
nisms of sensitization, validating P2X3 receptors as potential new targets in the treatment of
abdominal pain syndromes.
Introduction
Abdominal pain is a common symptom in many gastrointestinal disorders, among which the
irritable bowel syndrome (IBS) and inflammatory bowel disease (IBD). In IBD, the continuous
release of inflammatory mediators during flares can sensitize peripheral nerve endings in the
gut wall, resulting in disturbed sensitivity and abdominal pain, which is not only present during
acute flares of inflammation but also during remission [1,2]. In contrast in IBS, abdominal
pain and visceral hypersensitivity persist in the absence of overt colonic pathology [3]. Of note,
a specific subgroup of patients develops IBS after an episode of acute gastroenteritis, termed
post-infectious IBS [4]. Current treatments for IBD and IBS are mainly aimed at dampening
the intestinal inflammation (IBD) or normalizing the associated motility dysfunctions (IBS) to
indirectly reduce abdominal pain; in contrast, few therapeutics specifically target the afferent
nerves.
Extracellular adenosine 5’-triphospate (ATP) has been established as a key sensory signaling
molecule that activates purinergic P2X ligand-gated ion channel receptors and P2Y G-protein
coupled receptors [5]. There are seven P2X receptor subunits (P2X1-7) that can be assembled as
homo- or heteromultimers [6]. Especially P2X3 receptor units, expressed as homomeric P2X3
or heteromeric P2X2/3 receptors, are considered to play a major role in visceral sensory func-
tion and have been put forward as an interesting target in the pursuit of new treatments for vis-
ceral pain such as in IBS and IBD [7,8]. ATP, released from the epithelium lining cells upon
distension of hollow organs (e.g. gut, urinary and gall bladder and lung), acts on these P2X3
channels which are expressed on subepithelial nerves relaying the sensory information to the
central nervous system [5]. In addition, P2X3 receptors are the predominant purinergic recep-
tor subtypes present in the dorsal root ganglia (DRGs) [9,10]. They are found mainly on small
and medium-sized neurons, which are considered to be nociceptive C-fibers, but also on a sub-
population of Aδ-fibers [9,11,12]. Considering the predominant expression on nociceptive af-
ferent fibers, the role of purinergic signaling in visceral pain and hypersensitivity has been
intensively studied. However, so far the functional evidence implicating the P2X3 and P2X2/3
receptor subtypes in gut sensory signaling has come mainly from experiments using either
knock-out mice or nonselective P2X antagonists such as TNP-ATP, that acts on P2X3 and
P2X2/3 receptors but also displays nanomolar affinity for P2X1, or PPADS that blocks all types
of P2X receptors [13–20]. In contrast, the potential of specific P2X3 unit targeted therapy has
been hardly explored in animal models of gut hypersensitivity [20]. Nonetheless, such antago-
nists have already progressed to phase II clinical trials for hypersensitivity-associated disorders
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such as interstitial cystitis, osteoarthritis and idiopathic chronic cough (http://clinicaltrials.gov)
[11]. In addition, most studies have been conducted under physiological conditions or in ani-
mal models of acute chemically-induced visceral hypersensitivity [14–17,19,20]. Despite its rel-
evance from a clinical point-of-view, little in vivo evidence is available on the role of P2X3
receptor modulation of visceral sensory function in models of longer-lasting visceral pain.
Therefore, in this study we investigated the effect of A-317491, a selective and potent antag-
onist of P2X3 channels and evaluated its antinociceptive potential under physiological condi-
tions, during acute colitis and in a model for post-inflammatory visceral hypersensitivity. We
demonstrated that A-317491 dose-dependently reduced visceral hypersensitivity with a differ-
ent potency during acute colitis and in the post-inflammatory phase, without affecting visceral
nociception under physiological conditions.
Material and Methods
Animals
Male Sprague-Dawley rats (200–225 g) were obtained from Charles River. Animals were kept
in pairs at a constant room temperature (22 ± 2°C) and humidity (60%) and on a 12h:12h day-
night cycle. They were allowed to acclimatize to housing conditions for 1 week prior to experi-
mentation. All animal procedures were approved by the Ethical Committee for use of Experi-
mental Animals at the University of Antwerp (2010–18). Except for the assessment of visceral
sensitivity which requires rats to be fully awake, all procedures were performed under pento-
barbital anesthesia (45–100 mg/kg). All efforts were made to minimize animal suffering.
Induction of colitis
TNBS-colitis was induced after an overnight fast and under pentobarbital anesthesia (60 mg/kg)
by intrarectal administration of a 0.5 ml enema containing 15 mg of TNBS, dissolved in 50% eth-
anol [21,22]. Control rats were administered an intrarectal saline enema.
In vivomarkers of inflammation
Colonoscopy was performed to confirm the extent of colitis and to monitor convalescence lon-
gitudinally in time as previously described [21]. The lubricated tip of a baby gastroscope
(Olympus Europa GmbH) was inserted through the anus of the sedated rat and advanced
under endoscopic control for 10 cm. During withdrawal, TNBS-induced mucosal damage was
assessed using a standardized scoring system, taking into account the degree of ulceration, dis-
ease extent and the presence of edema, bleeding or stenosis (total score 0–19) [23].
Post-mortem markers of inflammation
At the end of the experiments, the distal colon was rapidly excised to evaluate macroscopic mu-
cosal damage using a validated scoring system (score 0–10) [23,24]. A representative section
was fixed in 4% formaldehyde for 24 h and embedded in paraffin for hematoxylin-eosin stain-
ing. Histological specimens (5 μm) were scored microscopically for the presence of an inflam-
matory infiltrate, the number of infiltrated layers, mucosal architectural distortion and edema
(score 0–10) [21,23]. A second representative 1 cm segment was used to assay myeloperoxidase
(MPO) activity according to our previously published methods [23]. In brief, specimens were
blotted dry and placed in a potassium phosphate buffer pH 6.0 containing 0.5% hexadecyltri-
methylammonium bromide (5 g per 100 ml buffer). The samples were arranged on ice, homog-
enized for 30 s and subjected to two sonication and freeze-thawing cycles. The suspension was
centrifuged at 15000 g for 15 min at 4°C. Aliquots (100 μl) of the supernatant were added to
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2.9 ml of o-dianisidine solution (16.7 mg of o-dianisidine in 1 ml saline, 98 ml of 50 mmol po-
tassium phosphate buffer, pH 6.0 and 1 ml of a 0.05% H2O2 solution as a substrate for MPO
enzyme). The change in absorbance was read at 460 nm over 60 s using a Spectronic Genesys
5 spectrophotometer (Milton Roy). One unit of MPO activity was defined as the quantity able
to convert 1 μmol H2O2 to H2O per min at 25°C and was expressed as units per gram of tissue
(U/g tissue).
Visceral sensitivity
Visceral sensitivity was assessed by quantifying the VMRs to colorectal distension [25,26]. The
VMR is a nociceptive reflex that integrates both peripheral and central mechanisms and con-
sists of the contraction of the abdominal musculature in response to noxious colorectal disten-
sion. Three to five days prior to VMR assessment, two Teflon-coated EMG electrodes were
sutured into the external oblique abdominal muscle and exteriorized at the base of the neck for
future access. On the day of visceral sensitivity testing, a lubricated balloon (5 cm length) was
carefully inserted in the colorectum up to 0.5 cm passed the anal verge. The balloon catheter
was secured to the tail and connected to a barostat system (Distender Series II Barostat, G&J
Electronics) for pressure-controlled, graded colorectal distensions (10–80 mmHg, 20 s, 4 min
interval). The EMG electrodes were relayed to a data acquisition system and the abdominal
EMG signal was recorded (NL100AK headstage), amplified (NL104), filtered (NL 125/126,
Neurolog, Digitimer Ltd, bandpass 50–5000 Hz) and digitized (CED 1401, Cambridge Elec-
tronic Design,) to a PC for off-line analysis using Spike2 version 5.16 for Windows (Cambridge
Electronic Design). The analog EMG signal was rectified and integrated. To quantify the mag-
nitude of the VMR at each distension pressure, the area under the curve (AUC) during disten-
sion (20 s) was corrected for the baseline activity (AUC pre-distension, 20 s).
Colonic compliance
Colonic compliance was studied in the same animal to exclude pharmacologically mediated
changes in the viscoelastic properties of the colonic wall as the mechanism of antinociception.
Rats were anesthetized (pentobarbital 45 mg/kg) and graded volumes of saline (0–2.5 ml) were
applied to the balloon inserted in the colorectum while recording the corresponding intracolo-
nic pressure.
ATP assay
ATP release was assayed as previously published [16,17]. Under deep pentobarbital anesthesia
(100 mg/kg) and after intrathoracic exsanguination, the distal colon was rapidly excised and
transferred to an organ bad, which was continuously perfused with oxygenated Krebs solution
(118 mMNaCl, 4.75 mM KCl, 1 mM NaH2PO4, 22 mM NaHCO3, 1.2 mMMgSO4, 2.5 mM
CaCl2, 11 mMD-glucose; 10 ml/min). The proximal and distal ends of the colon were secured
to an in- and outflow port respectively for intraluminal perfusion with Krebs solution that was
maintained at a constant rate of 1 ml/min via a perfusion syringe pump. Colorectal distension
was induced by closure of the outflow while maintaining the inflow, resulting in ramp disten-
sion (up to 60 mmHg). A pressure transducer was placed in parallel to monitor intracolonic
pressure. The distension fluid was collected, snap frozen and stored at -80°C. The concentra-
tion of ATP in the samples was quantified using a luciferin-luciferase ATP determination assay
(A22066; Invitrogen).
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Quantitative RT-PCR
Expression of P2X3 receptors and of cdk5, csk and CAS, molecular determinants of P2X3-mediat-
ed signaling, were quantified in the colon and dorsal root ganglia (DRGs). Colonic segments were
harvested from sites of representative macroscopic appearance. The DRGs contain the primary
afferent neurons conveying sensory information from the colon to the spinal cord and were har-
vested bilaterally at Th12-L2 and at L6-S1. Total RNAwas extracted from colon using the RNeasy
Minikit (Qiagen) and from DRGs using the Absolutely RNAmicroprep kit (Stratagene). RNA
was then converted to cDNA (Transcriptor First Strand cDNA Synthese Kit, Roche). A Taqman
gene expression assay (Applied Biosystems) was performed for P2X3 (Rn00579301_m1), cdk5
(Rn04219635_m1), csk (Rn01418228_m1) and CASK (Rn00573365_m1) on a ABIPrism 7300
sequent detector system (Applied Biosystems) in a 25 μl reaction volume containing 2 μl cDNA,
12.5 μl TaqMan Universal PCRmaster mix (Applied Biosystems), 1.25 μl Taqman assay probe
and 9.25 μl RNase-free H2O. The parameters for PCR amplification were 50°C for 2 min, 95°C
for 10 min, followed by 40 cycles of 95°C for 15 s and 60°C for 1 min. Expression was normalized
against the reference gene β-actin (Rn00667869_m1; Applied Biosystems; stable across tissues
and experimental conditions) for calculation of comparative cycle thresholds [ΔCT = CT(target
gene)—CT(β-actin)]. Relative expression of mRNA species was then determined as 2
-ΔΔCT with
ΔΔCT = ΔCT (TNBS)- ΔCT (control) [27].
Immunohistochemistry
Animals were transcardially perfused with 4% paraformaldehyde in phosphate buffer (pH 7.4).
The DRGs (Th13-L2 to L6-S1) were dissected out and post-fixed for 30 min. After PBS wash-
ing, DRGs were incubated in 0.01M PBS with 20% sucrose at 4°C overnight and embedded in
OCT medium for cryopreservation. Cryosections (9 μm) were thaw-mounted on poly-L-
lysine-coated microscope slides. As a blocking step, cryosections were incubated for 1 h with
0.01M PBS (pH 7.4) containing 0.05% thimerosal (PBS) supplemented with 10% normal
horse serum (NHS) and 1% Triton X-100. Goat polyclonal anti-CGRP (calcitonin gene-related
peptide; AB36001, 1:2500; Abcam) and rabbit polyclonal anti-P2X3 (AB5895, 1:500; Millipore)
were diluted in PBS supplemented with 10% NHS and applied overnight at room temperature.
After rinsing in PBS, tissues were incubated with Cy3-labeled donkey anti-goat (1:4000) and
FITC-labeled donkey anti-rabbit (1:300; both Jackson Immunoresearch) diluted in 0.01M PBS
(pH 7.4) and again rinsed in PBS. Cryosections were mounted in citifluor (Citifluor Ltd) and
visualized with fluorescence microscopy. For quantification, 3 thoracolumbal (Th13-L2) and
3 lumbosacral (L6-S1) DRGs were evaluated per animal (n = 3 animals per experimental condi-
tion: control, acute colitis, post-colitis). Three non-sequential cryosections were counted per
DRG for expression of CGRP, P2X3 and co-expression levels, as these were previously reported
to be enhanced in another animal model for visceral hypersensitivity [17].
Experimental protocol
Experiments were performed either during acute colitis or in the post-colitis phase (Fig 1). In
set-up 1, the role of P2X3 receptors in sensory signaling was investigated during acute colitis.
Rats were randomized to receive a saline (control) or TNBS enema and all experiments were
conducted 3 days later, during acute inflammation. In set-up 2, the contribution of P2X3 to vis-
ceral hypersensitivity was studied in the post-inflammatory phase of colitis. Rats were random-
ized to receive a saline (control) or TNBS (colitis) enema and the extent of inflammation was
verified colonoscopically on day 3. From day 10 onwards, convalescence was monitored indi-
vidually by repeated colonoscopy which was performed every 4 days. If at any time point
P2X3 Receptors Mediate Visceral Hypersensitivity
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colonoscopy still showed signs of mucosal inflammation, the animal was allowed to recover
further and colonoscopy was repeated 4 days later. If colonoscopy showed complete mucosal
healing, all experiments were conducted 3 days later.
In both the acute and post-colitis set-ups, rats received a single injection with A-317491,
a selective P2X3 receptor antagonist (10–25 mg/kg ip) or vehicle (saline ip) 30 min prior
VMR assessment, which was followed immediately by an evaluation of colonic compliance.
In each rat, colonoscopy, as well as macroscopic and microscopic evaluation of the colonic
tissue were performed in addition to an MPO activity assay to quantify inflammatory mar-
kers. To assess P2X3 receptor expression at the mRNA and protein level and quantify the ex-
pression of the intracellular signaling molecules of P2X3 signaling, the colon and DRGs were
harvested from drug-naive rats in the control, acute colitis and post-colitis groups. In addition,
colorectal distension was performed in vitro and the distension fluid was collected to assay
ATP release.
Statistical analysis
Data are presented as mean ± sem for n the number of animals per group. Variables were ana-
lyzed using unpaired Student’s t-test and one-way or two-way ANOVA followed by Student-
Newman-Keuls (SNK) post-hoc test when appropriate. Analysis of VMR and compliance data
was performed by the generalized estimating equation (GEE) model followed by least signifi-
cant difference (LSD) post-hoc test when appropriate. Statistical analysis was executed using
SPSS 20.0 software. Statistical significance was set at p<0.05.
Fig 1. Scheme of the two experimental set-ups. In set-up 1 (acute colitis), rats were instilled with TNBS (colitis) or saline (control) and further experiments
were conducted 3 days later, during the acute phase of colitis. In set-up 2 (post-colitis), rats were instilled with TNBS or saline and the extent of colitis and the
healing process were monitored individually by repeated colonoscopy: first on day 3 to confirm the presence of colitis and thereafter, starting from day 10,
every 4 days until complete mucosal healing (score = 0) occurred. Further experiments were conducted 3 days after colonoscopically proven mucosal
healing. A-317491 (10–25 mg/kg) or vehicle (saline), denoted by the injection needle, was administered 30 min prior to the start of the VMR protocol.
Evaluation of the inflammatory status entailed colonoscopy, macroscopic and microscopic assessment of the colonic tissue in addition to a myeloperoxidase
activity (MPO) assay. ATP, adenosine 5’-triphosphate; DRG, dorsal root ganglion; IHC, immunohistochemistry; RT-PCR, reverse transcription polymerase
chain reaction; TNBS, trinitrobenzene sulphonic acid; VMR, visceromotor response.
doi:10.1371/journal.pone.0123810.g001
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Results
Effect of P2X3 receptor blockade on visceral hypersensitivity during
acute TNBS-colitis
Three days after TNBS-instillation distal colitis was present, characterized by the presence of
multiple serpiginous ulcers, whereas no colonic damage was seen in controls. Inflammatory
markers were significantly increased in TNBS-instilled rats (Table 1).
VMRs to colorectal distension were markedly increased during acute TNBS-colitis com-
pared to controls, indicating the presence of acute inflammation-induced visceral hypersensi-
tivity (Fig 2A). This hypersensitivity was dose-dependently reduced by A-317491. After 10 mg/
kg of A-317491 VMRs were not significantly reduced at the highest distension pressures of 40–
80 mmHg but were markedly attenuated at the lower distension pressures (20 and 30 mmHg).
In contrast, 25 mg/kg significantly reduced hypersensitivity for almost the full range of disten-
sion pressures (20 to 80 mmHg) (Fig 2B). However, VMRs remained significantly increased
compared to controls at 10 to 30 mmHg distension. The 25 mg/kg dose did not affect VMRs in
the control group (Fig 2C).
Colonic compliance was assessed by distending the balloon in the colorectum with increas-
ing volumes of water which increased the intracolonic pressure in a volume-dependent fashion
(Fig 2D). Intracolonic pressures increased more rapidly during acute colitis, indicating reduced
colonic compliance compared to controls. The pressure-volume relationship was not modulat-
ed by either dose of A-317491. In addition, the single administration of A-317491 30 min be-
fore assessment of the VMR did not affect the colonoscopic, macroscopic or microscopic
appearance of the colonic tissue (Table 1).
Effect of P2X3 receptor blockade on post-inflammatory visceral
hypersensitivity
TNBS-instillation resulted in acute colitis, as evidenced by the colonoscopic scores on day 3
(Table 2). Colitis resolved spontaneously after a median of 14 days (range 10–14 days). Analy-
sis of the inflammatory markers confirmed the post-inflammatory status at the time of the ex-
periment (Table 2).
After resolution of TNBS-colitis, VMRs were significantly increased in post-colitis rats com-
pared to controls for the full range of distension pressures, indicating the presence of marked
post-inflammatory visceral hypersensitivity (Fig 3A). These increased VMRs were reduced by
A-317491. After a single administration of 10 mg/kg A-317491, VMRs were markedly
Table 1. Inflammatory status during acute TNBS-colitis.
Group Drug N Colonoscopy Macroscopy Microscopy MPO
(0–19) (0–10) (0–10) (U/g)
Control Vehicle n = 8 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 0.4 ± 0.1
25 mg/kg A-317491 n = 5 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 1.0 ± 0.6
Acute colitis Vehicle n = 8 7.0 ± 0.9 *** 6.3 ± 0.8 *** 4.4 ± 0.7 *** 16.5 ± 0.7 **
10 mg/kg A-317491 n = 8 7.3 ± 0.9 *** 6.0 ± 0.7 *** 4.6 ± 0.8 *** 27.7 ± 0.6 **
25 mg/kg A-317491 n = 8 6.5 ± 0.5 *** 4.4 ± 1.2 *** 3.2 ± 1.2 *** 14.9 ± 3.5 **
Results are presented as mean ± sem. Two-way ANOVA followed by SNK post-hoc test
** p<0.01
*** p<0.001, signiﬁcant effect of the factor colitis; no signiﬁcant effect of the factor drug; no interaction.
doi:10.1371/journal.pone.0123810.t001
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attenuated (Fig 3A). However VMRs remained significantly increased compared to controls at
20 mmHg distension. After treatment with 25 mg/kg A-317491, VMRs normalized over the
full range of distension pressures and were no longer significantly different from those of con-
trols at any of the distension pressures applied (Fig 3B). The highest dose of 25 mg/kg did not
affect VMRs in control rats (Fig 3C).
After resolution of TNBS-colitis, colonic compliance was similar in the control and post-co-
litis rats and was not altered by either dose of A-317491 (Fig 3D). In addition, A-317491 treat-
ment had no effect on inflammatory markers (Table 2).
Fig 2. Effect of A-314791 on VMRs and colonic compliance during acute TNBS-colitis. VMRs were assessed 3 days post-TNBS enema, immediately
followed by an evaluation of colonic compliance. A-314791 (filled symbols; 10–25 mg/kg) or vehicle (open symbols) was administered 30 min prior to VMR
assessment. Increased VMRs were present in rats with acute TNBS-colitis compared to controls and were dose-dependently reduced by 10 mg/kg (A) and
25 mg/kg (B) A-317491. The 25 mg/kg dose did not affect VMRs in healthy controls (C). To facilitate comparison, VMRs for vehicle-treated control rats are
also shown in A and B (gray dashed line). Generalized estimating equations, LSD post-hoc test, n = 5–8; * p<0.05, ** p<0.01, *** p<0.001, significantly
different from control + vehicle; # p<0.05, ## p<0.01, ### p<0.001, significantly different from acute colitis + vehicle. Colonic compliance was reduced during
acute TNBS-colitis, but remained unaffected by A-317491 (10–25 mg/kg) (D). Generalized estimating equations, LSD post-hoc test, n = 5–8; * p<0.05,
significant effect of the factor colitis.
doi:10.1371/journal.pone.0123810.g002
P2X3 Receptors Mediate Visceral Hypersensitivity
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Effect of P2X3 receptor blockade in acute inflammatory compared to
post-inflammatory visceral hypersensitivity
During acute colitis, A-317491 dose-dependently, but not fully reversed visceral hypersensitivi-
ty, even at the highest dose of 25 mg/kg (Fig 2). However, in post-colitis rats the 10 mg/kg dose
already normalized VMRs (Fig 3). To substantiate a difference in potency of A-317491 in re-
ducing visceral hypersensitivity between the acute phase of colitis and the post-inflammatory
phase, the effect of A-317491 on VMRs was expressed as the percentage of improvement or
normalization (Fig 4): 0% indicates no improvement (compared to vehicle-treated acute colitis
or post-colitis rats) whereas 100% accounts for full normalization of the VMRs (to the level of
vehicle-treated controls). In post-colitis rats both the 10 and the 25 mg/kg dose of A-317491
were more effective in reducing the increased VMRs compared to the effect of A-317491 in rats
in the acute phase of colitis (Fig 4).
ATP release in response to 60 mmHg of colorectal distension was significantly increased in
the distal colon of rats with acute TNBS-colitis (20.0 ± 6.4 pmol/ml; n = 11; p<0.05) compared
to controls (3.4 ± 2.2 pmol/ml; n = 8). In the post-colitis condition, ATP release was no longer
significantly different compared to controls (2.6 ± 0.9 pmol/l; n = 6).
The relative expression of P2X3 unit mRNA in the colon and DRGs was comparable in con-
trol, acute colitis and post-colitis rats (Table 3). Immunohistochemical staining of DRGs also
revealed no difference in expression of CGRP and P2X3 between control, acute colitis and
post-colitis conditions (Table 4; Fig 5). In addition, co-expression levels were similar between
all groups. However, RT-PCR did reveal a difference in the mRNA expression of cdk5, csk and
CASK, important molecular determinants of P2X3 receptor-mediated signaling (Table 3). Co-
lonic mRNA expression of all three targets was increased in the post-colitis group, whereas
mRNA levels were similar in the colon of acute colitis and control rats. The increased expres-
sion in post-colitis rats was specific for the colon and was not seen at the DRG level, although
we did find evidence of reduced csk mRNA expression in the DRGs L6-S1 (Table 3).
Discussion
This study was designed to evaluate P2X3 receptor contribution to visceral mechanosensitivity.
Our results indicate that P2X3-mediated signaling is not involved in colonic mechanosensitiv-
ity under physiological conditions, but contributes to a different extent to visceral hypersensi-
tivity during acute TNBS-colitis and in the post-inflammatory phase.
Table 2. Inflammatory status after the resolution of TNBS-colitis.
Group Drug N Colonoscopy (0–19) Macroscopy Microscopy MPO
day 3 after exp (0–10) (0–10) (U/g)
Control Vehicle n = 8 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 0.9 ± 0.4
25 mg/kg A-317491 n = 5 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 1.0 ± 0.3
Post-colitis Vehicle n = 8 5.2 ± 0.6 *** 0.3 ± 0.3 0.3 ± 0.3 0.3 ± 0.3 0.6 ± 0.2
10 mg/kg A-317491 n = 8 5.2 ± 0.6 *** 0.0 ± 0.0 0.3 ± 0.3 0.0 ± 0.0 1.2 ± 0.3
25 mg/kg A-317491 n = 7 5.3 ± 0.6 *** 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 0.6 ± 0.2
Results are presented as mean ± sem. Two-way ANOVA followed by SNK post-hoc test
*** p<0.001, signiﬁcant effect of the factor colitis; no signiﬁcant effect of the factor drug; no interaction. Exp, experiment.
doi:10.1371/journal.pone.0123810.t002
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P2X3 receptors do not contribute to colonic mechanosensitivity under
physiological conditions
In our experiments, A-317491 did not affect VMRs in control rats. A-317491 is a potent and
selective antagonist with nanomolar affinity for P2X3 units [20]. A-317491 shows very poor
central nervous system penetration and can thus be considered a peripherally acting blocker
[28,29]. Therefore, our results suggest that at least peripheral P2X3 receptors do not contribute
to colonic mechanosensitivity under physiological conditions, which is in line with previous
evidence [14,20]. Shinoda et al. [14] reported that pelvic afferent nerve discharge in response to
colorectal distension remained unaffected in P2X3
-/- mice. In the same study, VMRs in P2X3
-/-
mice were significantly attenuated whereas ATP release to colorectal distension remained unal-
tered, leading the authors to conclude that under physiological conditions only central, but not
peripheral P2X3 receptors contribute to colonic mechanosensitivity [14]. Such a central
Fig 3. Effect of A-314791 on VMRs and colonic compliance after the resolution of TNBS-colitis. VMRs were assessed 3 days after colonoscopically-
proven resolution of TNBS-colitis, immediately followed by an evaluation of colonic compliance. A-314791 (filled symbols; 10–25 mg/kg) or vehicle (open
symbols) was administered 30 min prior to VMR assessment. Increased VMRs were present in rats that had recovered from colitis compared to controls and
were normalized by 10 mg/kg (A) and 25 mg/kg (B) A-317491. The 25 mg/kg dose did not affect VMRs in healthy controls (C). To facilitate comparison,
VMRs for vehicle-treated control rats are also shown in A and B (gray dashed line). Generalized estimating equations, LSD post-hoc test, n = 5–8; * p<0.05,
*** p<0.001, significantly different from control + vehicle; # p<0.05, ## p<0.01, ### p<0.001, significantly different from acute colitis + vehicle. Colonic
compliance was similar in control and post-colitis rats and remained unaffected by A-317491 (10–25 mg/kg) (D). Generalized estimating equations, LSD
post-hoc test, n = 5–8.
doi:10.1371/journal.pone.0123810.g003
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mechanism of action could be located at the level of the spinal cord where presynaptic P2X3
channels facilitate the release of excitatory glutamate [11]. The lack of a peripheral contribution
of P2X3 to sensory signaling under physiological conditions is further suggested by the finding
that double P2X2
-/- P2X3
-/- mice show similar increases in jejunal afferent nerve firing in re-
sponse to gut distension compared to controls [13]. Likewise, the P2X1/P2X3 receptor antago-
nist TNP-ATP, which is also devoid of central nervous system penetration [30], did not affect
Fig 4. Effect of A-317491 in acute TNBS-colitis compared to the post-inflammatory phase of colitis. To substantiate a difference in potency of A-
317491 to reduce visceral hypersensitivity during acute TNBS-colitis compared to the post-inflammatory phase of colitis, data are expressed as the
percentage of improvement of normalization: 0%means no improvement and thus the same level of hypersensitivity as vehicle-treated rats during acute
TNBS-colitis or in the post-inflammatory phase, whereas 100%means complete normalization of the increased VMRs (reaching the level of vehicle-treated
controls). Both the 10 mg/kg (A) and the 25 mg/kg (B) dose of A-317491 more potently reduced visceral hypersensitivity in the post-inflammatory phase of
colitis compared to the acute inflammatory phase of colitis. Generalized estimating equations, LSD post-hoc test, n = 7–8; * p<0.05, significantly different
compared to acute colitis.
doi:10.1371/journal.pone.0123810.g004
Table 3. mRNA expression of P2X3, cdk5, csk and CASK in the colon and DRGs (Th13-L2 and L6-S1).
Tissue Target gene Control Acute colitis Post-colitis
(n = 7) (n = 5) (n = 7)
Colon P2X3 1.06 ± 0.16 1.12 ± 0.34 0.91 ± 0.09
cdk5 1.07 ± 0.16 0.86 ± 0.18 1.54 ± 0.16 #
csk 1.34 ± 0.38 0.48 ± 0.13 3.52 ± 0.60 *#
CASK 1.12 ± 0.20 1.10 ± 0.17 1.83 ± 0.21 #
Th13-L2 P2X3 0.95 ± 0.05 1.06 ± 0.12 1.08 ± 0.04
cdk5 1.29 ± 0.24 1.60 ± 0.12 1.69 ± 0.56
csk 1.11 ± 0.22 0.86 ± 0.08 0.77 ± 0.22
CASK 1.38 ± 0.26 1.56 ± 0.30 2.22 ± 1.18
L6-S1 P2X3 1.08 ± 0.09 0.86 ± 0.05 0.98 ± 0.05
cdk5 1.04 ± 0.12 0.79 ± 0.10 0.81 ± 0.15
csk 1.05 ± 0.14 0.83 ± 0.11 0.38 ± 0.08 * #
CASK 1.07 ± 0.18 0.97 ± 0.09 1.14 ± 0.78
Data presented as mean ± sem for n = 5–10 animals per group. One-way ANOVA followed by SNK.
* p<0.05, signiﬁcantly different from control
# p<0.05, signiﬁcantly different from acute-colitis.
doi:10.1371/journal.pone.0123810.t003
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in vivo nociceptive behavior to colorectal distension in rats under control conditions [18].
However in contrast, pelvic afferent nerve discharge to gut distension was significantly attenu-
ated by TNP-ATP in healthy control rats [16].
P2X3 receptors contribute to visceral hypersensitivity during acute
TNBS-colitis and in the post-inflammatory phase
Our in vivo data of increased purinergic signaling via P2X3 channels during acute TNBS-colitis
are in line with previous in vitro findings of Wynn et al. [17] who showed that pelvic afferent
nerve firing in response to colorectal distension was significantly increased in an isolated colon
segment from rats with acute TNBS colitis and that this increase could be attenuated by the
P2X receptor antagonist PPADS and the P2X1/P2X3 receptor antagonist TNP-ATP. Our study
elaborates on these results and now provides evidence from an in vivo set-up demonstrating
that the selective P2X3 antagonist A-317491 dose-dependently, though not fully, reversed the
increased VMRs to colorectal distension in rats with acute TNBS-colitis. This suggests that re-
ceptors containing the P2X3 unit contribute to visceral hypersensitivity during acute colitis.
This antinociceptive effect of the P2X3 receptor antagonist was not mediated by changes in co-
lonic compliance. This is important considering other antagonists such as TNP-ATP and
PPADS also block P2X1 receptors expressed on smooth muscle cells in the rat distal colon [31].
Table 4. Protein expression of CGRP and P2X3 in the dorsal root ganglia.
Staining DRG level Control Acute colitis Post-colitis
Number of positive neurons per mm2
CGRP Th13-L2 47 ± 17 59 ± 25 74 ± 33
L6-S1 32 ± 15 28 ± 11 35 ± 8
P2X3 Th13-L2 29 ± 6 38 ± 18 55 ± 21
L6-S1 30 ± 17 16 ± 5 32 ± 6
% of co-expressing neurons
P2X3 /CGRP co-expression Th13-L2 9 ± 3% 4 ± 1% 6 ± 2%
L6-S1 6 ± 1% 8 ± 3% 11 ± 4%
CGRP/P2X3 co-expression Th13-L2 13 ± 4% 7 ± 1% 8 ± 3%
L6-S1 7 ± 2% 14 ± 4% 12 ± 4%
Data presented as mean ± sem for n = 3 animals per group and 3 DRGs per animal for each level. DRGs, dorsal root ganglia. Two-way ANOVA, no
signiﬁcant effects.
doi:10.1371/journal.pone.0123810.t004
Fig 5. Expression of CGRP and P2X3 in dorsal root ganglia. Immunohistochemical detection of CGRP (left panel) and P2X3 (middle panel) on
cryosections of a dorsal root ganglion. The right panel shows the merged picture; the white arrows indicate neuronal co-expression of CGRP and P2X3.
doi:10.1371/journal.pone.0123810.g005
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Moreover, P2X3 receptors on myenteric neurons contribute to the initiation of reflex contrac-
tions when the intestinal pressure rises and could therefore modulate colonic compliance [32].
In a rat model for non-inflammatory visceral pain, induced by intraperitoneal injection of
acetic acid, A-317491 has previously been shown to reduce nociception with an IC50 of
27 μmol/kg, which is approximately 15 mg/kg [20]. On the other hand, A-317491 had no effect
on VMRs in a zymosan-induced model of acute colonic inflammatory hypersensitivity, even
after administration of 100 μmol/kg (approximately 56.6 mg/kg) [20]. We can only speculate
on the reasons underlying the discrepancy in the results between the latter study and our own
findings. Firstly, the difference in experimental models for visceral hypersensitivity should be
considered (TNBS vs zymosan). Secondly, in the zymosan-study, Sprague-Dawley rats were
subjected to 3 colorectal distension protocols: the first before the induction, the second during
acute colitis and the third 30 min after the second distension. In our hands, repeating disten-
sion protocols after a 30 min interval in male Sprague-Dawley rats induced hypersensitivity in
control rats (data not shown), which might relate to differences in the distension protocol (6
distensions ranging from 10 to 80 mmHg vs three 60mmHg distensions). Therefore, only one
distension protocol was performed in each rat in our set-up. In support of our results, A-
317491 also exerted antinociceptive effects in models of somatic and neuropathic pain
[20,29,33–35].
We additionally studied the effect of blockade of P2X3 receptor units in a rat model for
post-inflammatory visceral hypersensitivity. In this model, we confirmed the resolution of
TNBS-colitis by colonoscopic, macroscopic and microscopic evaluation of the colonic tissue, in
addition to MPO activity. Despite the absence of inflammation, the VMRs to colorectal disten-
sion were increased in post-colitis rats. These increased VMRs were dose-dependently reduced
and even normalized by A-317491. This strongly suggests an important role for P2X3 receptor
units in post-inflammatory visceral hypersensitivity. A contribution of purinergic P2X recep-
tors to post-infectious visceral hypersensitivity was previously suggested by Rong et al. [13]
who demonstrated that the P2X receptor antagonist PPADS reduced increased jejunal afferent
firing after Trichinella spiralis infection. Yet the exact P2X receptor subtype involved remained
to be identified. Our study now provides evidence of enhanced P2X3 unit-mediated signaling
in the post-inflammatory phase.
Evidence for a role for purinergic modulation of nociceptive responses, most likely mediated
by P2X3 receptor units, has also been reported in other animal models of visceral hypersensitiv-
ity. Xu et al. [18] instilled acetic acid in the colon of neonate rats, which resulted in visceral
hypersensitivity at the adult age; TNP-ATP reduced these increased VMRs. In addition, the
intracolonic instillation of zymosan in control mice induced visceral hypersensitivity in the ab-
sence of overt colonic inflammation, while VMRs remained unaffected by zymosan exposure
in P2X3
-/- mice [14]. Therefore, it seems that peripheral P2X3 receptor units contribute to vis-
ceral hypersensitivity, not only during and after the resolution of TNBS-colitis but also in other
types of chemically-induced colonic hypersensitivity.
Another novel finding in this study is that the potency of A-317491 to reduce visceral hyper-
sensitivity was different between acute colitis and the post-inflammatory phase. Visceral hyper-
sensitivity during the acute inflammation was attenuated but not fully reversed by 25 mg/kg A-
317491, whereas 10 mg/kg A-317491 almost completely normalized the increased visceral pain
in the post-inflammatory phase. The difference in percentage of improvement between acute
colitis and the post-inflammatory phase was statistically significant for both 10 and 25 mg/kg
of A-317491. Of note, by expressing the degree of improvement as a percentage, we corrected
for the tendency of higher VMRs in vehicle-treated rats during acute TNBS-colitis compared
to vehicle-treated post-colitis rats.
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Several mechanisms could underlie the difference in potency of A-317491 in reducing vis-
ceral hypersensitivity between the acute phase of colitis and the post-inflammatory phase.
Firstly, there was a significant increase in distension-induced release of ATP, the endogenous
ligand for P2X3 receptors, during acute colitis whereas ATP release had returned to control val-
ues in the post-inflammatory condition. ATP is present in the cell in millimolar concentrations
and during inflammation, extracellular ATP levels increase due to active release as well as pas-
sive leakage from damaged or dying cells, in combination with a downregulation of ATP break-
down [36]. Being a competitive antagonist for the P2X3 unit, A-317491 can be displaced from
the binding site by excess ATP [20]. In addition, at the level of the primary sensory afferent,
ATP potentiates the effect of other known nociceptive mediators such as protons, capsaicin
and 5-hydroxytryptamine [37]. Therefore the increased availability of extracellular ATP during
acute TNBS-colitis, most likely contributes to the enhanced P2X3-mediated signaling during
the acute inflammatory phase. Secondly, differences in the P2X3 receptor expression in the
acute versus the post-inflammatory phase may also contribute to the difference in A-317491
potency. However, we found no evidence of altered P2X3 expression at the mNRA or protein
level in the colon or DRGs, neither during acute colitis nor in the post-inflammatory phase, ar-
guing against a significant increase in P2X3 receptors in our study. In addition, we could not
demonstrate enhanced colocalization between P2X3 and CGRP either. In contrast, enhanced
colocalization during acute TNBS-colitis as was previously reported by Wynn et al. [17]. Be-
sides increased mediator release or increased receptor expression, sensitization of P2X3 recep-
tors may provide a plausible explanation for these results. The signaling of extracellular ATP
binding to P2X3 receptor is transduced in the intracellular environment by a series of adaptor
and scaffold molecules among which are kinases such as Cdk5, Csk, and CASK. Cdk5 and Csk
modulate the electrical properties of P2X3 receptors whereas CASK interacts with the P2X3
receptor to positively enforce the receptor’s stability and functional responsiveness [38].
To investigate their involvement, we performed RT-PCR for Cdk5, Csk and CASK mRNA
expression in the colon and DRGs (Th13-L2 and L6-S1) of control, acute colitis and post-colitis
rats. We found that in the post-colitis group, colonic mRNA expression of all three targets was
significantly increased, whereas mRNA levels were similar in acute colitis and controls. The in-
creased expression in the post-colitis group was specific for the colon and was not seen at the
DRG level. These findings point towards P2X3 receptor sensitization in the post-colitis phase,
that may underlie—or at least contribute to—the persistent post-inflammatory visceral hyper-
sensitivity in our study.
The observation of an increased potency of A-317491 to reduce hypersensitivity in the post-
colitis phase compared to the acute inflammatory event is an interesting observation that war-
rants further study. In fact few studies compare mediator contribution to hypersensitivity in an
acute versus a post-inflammatory setting. Similar evidence was presented for acid sensing ion
channels type 3 (ASIC3), as these were upregulated during active Crohn’s disease and contrib-
uted to peripheral sensitization by inflammatory mediators but were not involved in non-in-
flammatory visceral hypersensitivity according to another group [39–41]. To further
investigate whether this increased potency in the post-inflammatory phase is specific for P2X3
receptor mediated signaling, we conversely compared the antinociceptive effect of a selective
histamine H1 receptor antagonist levocetirizine in the acute and post-inflammatory setting (S1
Fig). We recently demonstrated that levocetirizine fully reversed post-inflammatory visceral
hypersensitivity in the post-inflammatory phase at a dose of 1 mg/kg [21]. Similar to our results
for A-317491, levocetirizine was more effective in reducing hypersensitivity in the post-inflam-
matory phase compared to the effect during acute TNBS-colitis (S1 Fig). As H1 receptors con-
tribute to afferent nerve signaling in the gut wall [42], this suggests a more general
upregulation of visceral afferent sensitivity in the post-inflammatory phase of TNBS-colitis.
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In summary, we evaluated the antinociceptive effects of A-317491, a selective P2X3-unit an-
tagonist, on visceral pain. A-317491 dose-dependently reduced visceral hypersensitivity during
acute TNBS-colitis and fully abolished increased VMRs after resolution of colitis without af-
fecting visceral sensitivity in controls. The antinociceptive effect of A-317491 was more pro-
nounced in the post-inflammatory phase of colitis compared to the acute inflammatory phase,
most likely due to displacement of A-317491 by excess ATP release during acute TNBS-colitis
and sensitization of P2X3 receptors in the post-inflammatory phase of colitis.
Hence, purinergic P2X3 receptor units do not seem to be involved in sensory signaling
under physiological conditions but mediate visceral hypersensitivity with a different potency
during acute TNBS-colitis and in the post-inflammatory phase. These findings validate P2X3
receptors as a potential new target in the treatment of abdominal pain syndromes such as IBS
and IBD.
Supporting Information
S1 Fig. Levocetirizine in acute TNBS-colitis compared to the post-inflammatory phase of
colitis. Data are expressed as the percentage of improvement of normalization: 0% means no
improvement and thus the same level of hypersensitivity as vehicle-treated rats during acute
TNBS-colitis or in the post-inflammatory phase, whereas 100% means complete normalization
of the increased VMRs (reaching the level of vehicle-treated controls). Levocetirizine (1 mg/kg)
more potently reduced visceral hypersensitivity in the post-inflammatory phase of colitis com-
pared to the acute inflammatory phase of colitis. Generalized estimating equations, LSD post-
hoc test, n = 5–8;  p<0.05, significantly different compared to acute colitis.
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